Effect of colistin consumption and prevalence of colistin-resistant bacteria;Vliv spotřeby kolistinu na výskyt kolistin- rezistentních bakterií

Klinicka Mikrobiologie a Infekcni Lekarstvi

Volumn 19, Issue 2, 2013, Pages 52-55

  Hanulík, Vojtěch ^a   Suchankova H ^b   Urbanek K ^b   Imwensi, P ^a   Htoutou Sedlakova M ^a   Vojtova V ^b   Kolar M ^a  

^a UNIVERSITY HOSPITAL OLOMOUC   (Czech Republic)

^b PALACKÝ UNIVERSITY   (Czech Republic)

Author keywords

Colistin; Consumption; RDDD; Resistance

Indexed keywords

COLISTIN; ANTIINFECTIVE AGENT;

ACINETOBACTER; ANTIBIOTIC RESISTANCE; ARTICLE; BURKHOLDERIA CEPACIA COMPLEX; CITROBACTER; ENTEROBACTER; ESCHERICHIA COLI; HUMAN; INTENSIVE CARE UNIT; KLEBSIELLA; KLEBSIELLA PNEUMONIAE; MORGANELLA MORGANII; NONHUMAN; PREVALENCE; PROTEUS; PROVIDENCIA; PSEUDOMONAS; PSEUDOMONAS AERUGINOSA; SERRATIA MARCESCENS; STENOTROPHOMONAS MALTOPHILIA; AGED; BACTERIUM; DRUG EFFECTS; ISOLATION AND PURIFICATION; RETROSPECTIVE STUDY;

AGED; ANTI-BACTERIAL AGENTS; BACTERIA; COLISTIN; DRUG RESISTANCE, BACTERIAL; HUMANS; PREVALENCE; RETROSPECTIVE STUDIES;

EID: 84881415106     PISSN: 1211264X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (12)

1. Falagas ME, Kasiakou SK. Colistin - the revival of polymyxins fot the management of multidrug-resistant gram-negative bacterial infections. Clin Infect Dis. 2005;40:1333-1341. (Pubitemid 40570245)
2. st century. Curr Opin Infect Dis. 2009;22:535-543.
3. Vaara M. Novel derivates of polymyxins. J Atimicrob Chemother 2013;68(6):1213-1219.
4. Boisson M, Grégoire N, Couet W, Mimoz O. Colistin in critically ill patients. Minerva Anestesiol. 2013;79:200-208.
5. Florescu DF, Qui F, McCartan MA, et al. What is the efficacy and safety of colistin for the treatment of ventilator-associated pneumonia? A systematic review and meta-regression. Clin Infect Dis. 2012;54:670-680.
6. Giamarellou H. Multidrug-resistant Gram-negative bakteria: how to treat and for how long. Int J Antibicrob Agents. 2010;36:S50-54.
7. European Committee on Antimicrobial Susceptibility Testing. Breakpoints tables for interpretation of MICs and zone diameters. Available from: http://www.eucast.org/clinical-breakpoints.
8. Anatomical therapeutic chemical (ATC) index (including defined daily doses (DDDs) for plain substances) Oslo: WHO collaboration centre for drug statistics methodology, 1996.
9. Bergman U, Christerson I, Jansson B, Wiholm BE. Auditing drug utilization by means of defined daily dose per bed-day. A methodological study. Eur J Clin Pharmacol. 1980;17:183-187. (Pubitemid 10109215)
10. Hanulík V, Chromá M, Webber MA, et al. Záchyt kmenů Burkholderia cepacia komplex ve Fakultní nemocnici Olomouc. Klin Mikrobiol Infekc Lek. 2012;18:4-8.
11. Uvizl R, Hanulik V, Husickova V, et al. Hospital-acquired pneumonia in ICU patients. Biomed Pap Med Fac Univ Palacky Olomouc Czech Republ. 2011;155:373-378.
12. Capone A, Giannella M, Fortini D, et al. High rate of colistin resistance among patients with carbapenem-resistant Klebsiella pneumoniae infection accounts for an excess of mortality. Clin Microbiol Infect. 2013;19:E23-30.